Report from the Front: a Glimpse at Breast Cancer Research in Low- and Middle-Income Countries

Purpose of Review Breast cancer is increasingly more prevalent in low- and middle-income countries (LMICs) and its biology in these populations may differ from that in more affluent countries. Research in these settings is limited by both societal factors and the lack of resources. Our intent is to review the parameters that limit more extensive research activities in LMICs and potentially investigate options for improvement. Findings LMIC governments have limited infrastructure to support appropriate research and the physicians are overburdened by clinical work. Even the patients fail to see the value of research in some countries. Funding and support from pharmaceutical companies is usually channeled to higher income countries with advanced infrastructure. Recent research demonstrates the multi-faceted problems with the conduct of clinical studies in LMICs. A concerted effort by the state and physicians can lead to the development of conditions conducive to research. Such efforts are of paramount importance as the potential of research activities in LMICs is very significant and capacity building can bring in funding, new medications, and ultimately better care for breast cancer patients in LMICs.